Spencer Knight: In vivo CART-T landscape
Spencer Knight,
“In vivo CART-T landscape: In vivo CAR-T therapy is an innovative approach that modifies a patient’s immune cells directly within their body, eliminating the need for complex and time-consuming ex vivo processing. This therapy involves the insertion of synthetic receptors (CARs) onto the surface of T cells, enabling them to target/attack cancer cells with specific surface proteins.
Three Pillars of In Vivo CAR-T:
1. In vivo CAR-T therapy promises speed/expedited treatment processes.
2. The direct modification within the patient’s body enhances treatment accessibility.
3. The potential for reduced costs positions in vivo CAR-T as a cost-effective cancer treatment.
Despite its promises, in vivo CAR-T therapy introduces safety concerns tied to delivery methods and off-target effects. Consequently, continuous research and clinical trials are imperative to assess its safety and efficacy across diverse cancer types and patient demographics.
(Credit to William Blair and highlighted company reports).
P.S. – Want to stay ahead of the biotech revolution? Sign up for FREE to my CGT weekly newsletter and discover the newest companies, clinical updates and breakthroughs this week, here.”
Source: Spencer Knight/LinkedIn